AUPH | Ticker Profile - Titan Protect

AUPH

Aurinia Pharmaceuticals Inc.

Healthcare · Biotechnology · NGM

$15.84

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.0B

Total market value of the company

Trailing P/E

7.19

Very cheap relative to earnings

Forward P/E

13.90

Based on estimated future earnings — lower means cheaper

Rev Growth

+24.4%

Year-over-year revenue change

Profit Margin

100.0%

How much profit the company keeps from each dollar of revenue

ROE

65.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.00

+7% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 7 analysts covering this stock

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

https://www.auriniapharma.com

Country: Canada Employees: 128 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

1.458

Excellent risk-adjusted returns

Kelly Fraction

0.0947

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.354

Returns exceed worst-case losses — strong risk profile

Annual Return

73.0%

Historical annualised return based on price data

Max Drawdown

-31.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

140

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.45

Moves slightly more than the broader market

52W High

$16.88

6% below the year high

52W Low

$7.29

117% above the year low

Avg Volume

1,192,370

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.8%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.09

Heavy leverage — higher financial risk if revenues decline

Current Ratio

5.55

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.95

Like current ratio but excludes inventory — stricter test

Gross Margin

78.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

53.3%

Profit from core operations before interest and tax

Free Cash Flow

$125M

Positive — the business generates more cash than it spends

Revenue (TTM)

$298M

Total revenue over the last 12 months

Net Income

$298M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$21.00

Target Median

$17.00

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go